Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Cong

Event · Earnings
Original reporting
Published Aug 11, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$COAG
Bullish
high confidence
Mentioned
$COAG
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COAGBullishMed
01

Why it matters

The most decision-relevant item is FDA endorsement to proceed to a Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia, including a planned 2H 2026 initiation and a specified weekly dose regimen. Additional updates include new HMB-002 first-in-human data and LTE data for sutacimig, plus the unveiling of HMB-003.

02

Market read

Traders can act on a concrete regulatory milestone (Phase 3 go-ahead) and the planned Phase 3 start window, while treating other conference data as supportive but less definitive.

03

What to watch

Phase 3 success risk remains high; the filing does not provide Phase 3 endpoints, enrollment timeline, or funding/cash runway details in the excerpt, which can cap upside.

Relevance 7/10Novelty 7/10Timing: today’s SEC 8-K, with Phase 3 initiation planned for 2H 2026

Background

This is an SEC Form 8-K (Item 2.02) where Hemab reports Q2 2026 financial results and provides a corporate update on multiple pipeline programs presented at ISTH 2026.

Company-level read

Ticker impact

$COAGBullishHigh confidence
Context

Hemab’s 8-K reports Q2 2026 results plus FDA endorsement to proceed to a Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia, planned 2H 2026.

Expected impact

Likely positive near-term bias as traders price the Phase 3 start timing and FDA acceptance of the data package.

Evidence & confidence

The filing explicitly states FDA endorsed the clinical data package as sufficient for a Phase 3 pivotal trial with a specified dose and planned initiation in 2H 2026, which is a concrete catalyst beyond routine conference updates.

Market effects

Supports sentiment for bleeding-disorder biotech development, especially non-replacement and prophylactic approaches in VWD and GT.

Limited direct regional impact; company highlights span US FDA and European regulators (EMA, MHRA).

Moderate, as the catalyst is FDA-driven but the company also references European designations and ISTH congress data.

Counterpoint

Conference and early clinical readouts (e.g., HMB-002 descriptive observations) may not translate into Phase 3 efficacy, so the market may overreact to mechanistic/proof-of-mechanism signals.

Key entities

  • Hemab Therapeutics Holdings, Inc.

    Clinical-stage biotech developing therapies for blood coagulation disorders; subject of the 8-K and pipeline update.

  • Sutacimig

    Bispecific antibody in clinical development for Glanzmann thrombasthenia and Factor VII deficiency; FDA endorsed data package for Phase 3 in GT.

  • HMB-002

    Monovalent antibody for subcutaneous prophylactic treatment of von Willebrand disease; presented proof-of-mechanism and descriptive bleed observations.

  • HMB-003

    Novel non-hormonal peptide antifibrinolytic for heavy menstrual bleeding and other bleeding settings; unveiled in the update.

  • FDA

    Endorsed Hemab’s sutacimig clinical data package as sufficient to proceed to a Phase 3 pivotal trial in GT.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A